Technologieangebote

Cardiac hypertrophy is characterized by a global increase in transcription and protein per cell. Cyclin-dependent kinase 9 (CDK9) is the main driver for transcription and is necessary for hypertrophy in cardiomyocytes. DKFZ scientists have shown that wogonin is a potent inhibitor of CDK9 with no or very low toxicity to normal tissues. Wogonin can be used for preventing cardiac hypertrophy.

The Wnt signaling pathway plays an important role in the regulation of cell proliferation and differentiation. Aberrant activation of the Wnt signaling pathway is known to promote uncontrolled cell growth and survival. Compound library screening and med-chem based structure activity improvement revealed potent Wnt signaling inhibitors that selectively affected carcinoma cell lines. In addition, further experiments proved these compounds to induce apoptosis.

The current technology demonstrates that treatment with ciprofloxacin leads to immunosuppression of T-cells isolated from patients with atopic dermatitis.

The invention proposes to use the travelling wave concept, but to couple high frequency waves only into an object to be investigated. However, in contrast to the prior art, the high frequency device enables to couple in RF waves targeted into a particular section of interest of the object. This offers the advantage that the excluded parts are not unnecessarily exposed to the RF waves and do not contribute to RF expo-sure limit calculations, which allows for a coupling in of a larger dose of the RF energy at a location where it is required. The hardware MRI device has a coaxial arrangement of tubular elements.

90% of sporadic colorectal carcinomas carry loss-of-function mutations in the adenomatous polyposis coli (APC) gene, which encodes a scaffolding protein mediating constitutive destruction of the ?-catenin transcriptional co-activator in the absence of Wnt ligand. DKFZ inventors detected NKD1 and C10orf54 as biomarkers for identification of Wnt/?-catenin modulating compounds, such as small molecules, interfering RNAs, peptides and antibodies and thus can be used for the development of a kit or an assay for detection of such compounds. This kit or assay can additionally be used as a companion diagnostic resource to identify patients in need of a treatment that modulates the Wnt/?-catenin signaling pathway (e.g. targeted therapy).

The technology is a method for determining the in vivo localization of double-strand breaks in a host cell using a linear polynucleotide.